Changes in metformin use in chronic kidney disease

Changes in metformin use in chronic kidney disease

Metformin is one of the oldest and most widely prescribed antidiabetic medicines worldwide. It is the only such medicine that has shown a reduction of cardiovascular mortality in diabetes mellitus type 2. Since many diabetic patients have chronic kidney disease, its use is often curtailed by practitioners due to fear of lactic acidosis and the US Food and Drug Administration (FDA) warnings that...

Vitamin deficiencies in chronic kidney disease

Endocrine disorders in chronic kidney disease

Background and Objective: Endocrine disorders are common in patients with chronic kidney disease (CKD). The aim of the present study is reviewing available literature to give a deep understanding of complexities of endocrine disorders in chronic kidney disease. Methods: A narrative reviewing method based on the available literature was approached. Findings: Generally, when renal function de...

Metformin: the safest hypoglycaemic agent in chronic kidney disease?

Metformin is the first-line oral agent in the treatment of type 2 diabetes and has many established benefits, including the reduction of macrovascular complications of diabetes. Its prescription in patients with renal impairment is limited by concerns relating to the theoretical risk of lactic acidosis, a fear which is perpetuated by numerous case reports in which it is implicated. Critical rev...

Metformin therapy in patients with chronic kidney disease.

Metformin therapy is limited in patients with chronic kidney disease (CKD) due to the potential risk of lactic acidosis. This open-label observational study investigated metformin and lactate concentrations in patients with CKD (n = 22; creatinine clearances 15-40 ml/min) and in two dialysed patients. Patients were prescribed a range of metformin doses (250-2000 mg daily) and metformin concentr...